|
[1]
|
Shastri, A., Al Aiyan, A., Kishore, U. and Farrugia, M.E. (2023) Immune-Mediated Neuropathies: Pathophysiology and Management. International Journal of Molecular Sciences, 24, Article No. 7288. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Rajabally, Y. (2024) Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Current Therapeutic Approaches and Future Outlooks. ImmunoTargets and Therapy, 13, 99-110. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Briani, C. and Visentin, A. (2026) Immunotherapies in Chronic Immune-Mediated Neuropathies. In: Handbook of Clinical Neurology, Elsevier, 345-356. [Google Scholar] [CrossRef]
|
|
[4]
|
Oaklander, A.L., Lunn, M.P., Hughes, R.A., van Schaik, I.N., Frost, C. and Chalk, C.H. (2017) Treatments for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): An Overview of Systematic Reviews. Cochrane Database of Systematic Reviews, 2017, CD010369. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Kiers, L. and Cruse, B. (2025) Evaluation and Treatment of Refractory Chronic Inflammatory Demyelinating Polyradiculoneuropathy. BMJ Neurology Open, 7, e001318. [Google Scholar] [CrossRef]
|
|
[6]
|
Min, Y.G., Visentin, A., Briani, C. and Rajabally, Y.A. (2025) Neuropathy with Anti-Myelin-Associated Glycoprotein Antibodies: Update on Diagnosis, Pathophysiology and Management. Journal of Neurology, Neurosurgery & Psychiatry, 96, 340-349. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Van den Bergh, P.Y.K., van Doorn, P.A., Hadden, R.D.M., Avau, B., Vankrunkelsven, P., Allen, J.A., et al. (2021) European Academy of Neurology/Peripheral Nerve Society Guideline on Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Report of a Joint Task Force—Second Revision. European Journal of Neurology, 28, 3556-3583. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Kuwabara, S. (2024) Typical CIDP: Update of the Pathogenesis, Diagnosis, and Treatment. Brain and Nerve, 76, 515-519. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
中华医学会神经病学分会, 中华医学会神经病学分会周围神经病协作组, 中华医学会神经病学分会肌电图与临床神经电生理学组, 中华医学会神经病学分会神经肌肉病学组. 慢性炎性脱髓鞘性多发性神经根神经病诊治中国专家共识2022 [J]. 中华神经科杂志, 2023, 56(2): 125-132.
|
|
[10]
|
Muley, S.A., Jacobsen, B., Parry, G., Usman, U., Ortega, E., Walk, D., et al. (2020) Rituximab in Refractory Chronic Inflammatory Demyelinating Polyneuropathy. Muscle & Nerve, 61, 575-579. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Benedetti, L., Briani, C., Franciotta, D., Fazio, R., Paolasso, I., Comi, C., et al. (2011) Rituximab in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Report of 13 Cases and Review of the Literature. Journal of Neurology, Neurosurgery & Psychiatry, 82, 306-308. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Doneddu, P.E., Cocito, D., Fazio, R., Benedetti, L., Peci, E., Liberatore, G., et al. (2024) Prospective Open-Label Trial with Rituximab in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy Not Responding to Conventional Immune Therapies. Journal of Neurology, Neurosurgery & Psychiatry, 95, 838-844. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Du, Y., Yan, Q., Li, C., Zhu, W., Zhao, C., Hao, Y., et al. (2024) Efficacy and Safety of Combined Low‐Dose Rituximab Regimen for Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Annals of Clinical and Translational Neurology, 12, 180-191. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Nobile-Orazio, E., Cocito, D., Manganelli, F., Fazio, R., Lauria Pinter, G., Benedetti, L., et al. (2025) Rituximab versus Placebo for Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Randomized Trial. Brain, 148, 1112-1121. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Wang, J. and Xiang, Q. (2024) Successful Treatment of Relapsed and Refractory CIDP with Ofatumumab: A First Case Report. Frontiers in Immunology, 15, Article ID: 1437848. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Casertano, S., Signoriello, E., Rossi, F., Di Pietro, A., Tuccillo, F., Bonavita, S., et al. (2020) Ocrelizumab in a Case of Refractory Chronic Inflammatory Demyelinating Polyneuropathy with Anti‐Rituximab Antibodies. European Journal of Neurology, 27, 2673-2675. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Dalakas, M.C. and Spaeth, P.J. (2021) The Importance of FcRn in Neuro-Immunotherapies: From IgG Catabolism, fcgrt Gene Polymorphisms, IVIg Dosing and Efficiency to Specific FcRn Inhibitors. Therapeutic Advances in Neurological Disorders, 14. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Allen, J.A., Lin, J., Basta, I., Dysgaard, T., Eggers, C., Guptill, J.T., et al. (2024) Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (ADHERE): A Multicentre, Randomised-Withdrawal, Double-Blind, Placebo-Controlled, Phase 2 Trial. The Lancet Neurology, 23, 1013-1024. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Levine, T. and Muley, S. (2025) Early Deterioration of CIDP Following Transition from IVIG to FcRn Inhibitor Treatment. Journal of the Neurological Sciences, 468, Article ID: 123313. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Querol, L., De Sèze, J., Dysgaard, T., Levine, T., Rao, T.H., Rivner, M., et al. (2024) Efficacy, Safety and Tolerability of Rozanolixizumab in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Randomised, Subject-Blind, Investigator-Blind, Placebo-Controlled, Phase 2a Trial and Open-Label Extension Study. Journal of Neurology, Neurosurgery & Psychiatry, 95, 845-854. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Querol, L.A., Hartung, H., Lewis, R.A., van Doorn, P.A., Hammond, T.R., Atassi, N., et al. (2022) The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. Neurotherapeutics, 19, 864-873. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Querol, L., Lewis, R.A., Hartung, H., Van Doorn, P.A., Wallstroem, E., Luo, X., et al. (2023) An Innovative Phase 2 Proof‐of‐Concept Trial Design to Evaluate SAR445088, a Monoclonal Antibody Targeting Complement C1s in Chronic Inflammatory Demyelinating Polyneuropathy. Journal of the Peripheral Nervous System, 28, 276-285. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Mevorach, D., Reiner, I., Grau, A., Ilan, U., Berkun, Y., Ta‐Shma, A., et al. (2016) Therapy with Eculizumab for Patients with CD59 P.cys89tyr Mutation. Annals of Neurology, 80, 708-717. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Pitarokoili, K., Yoon, M., Kröger, I., Reinacher-Schick, A., Gold, R. and Schneider-Gold, C. (2017) Severe Refractory CIDP: A Case Series of 10 Patients Treated with Bortezomib. Journal of Neurology, 264, 2010-2020. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Burt, R.K., Balabanov, R., Tavee, J., Han, X., Sufit, R., Ajroud-Driss, S., et al. (2020) Hematopoietic Stem Cell Transplantation for Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Journal of Neurology, 267, 3378-3391. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Zheng, Y., Hu, J., Sun, C., Zhao, C. and Lin, J. (2023) Efficacy of Hematopoietic Stem Cell Transplantation Treatment in Refractory Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta‐Analysis. European Journal of Neurology, 30, 2570-2582. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Dong, M., Mei, Z., Zhou, L., Heming, M., Xu, L., Liu, Y., et al. (2025) Anti-bcma CAR-T Cell Therapy in Relapsed/Refractory Chronic Inflammatory Demyelinating Polyneuropathy. Med, 6, Article ID: 100704. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Claytor, B., Polston, D. and Li, Y. (2025) Multifocal Motor Neuropathy: A Narrative Review. Muscle & Nerve, 71, 512-534. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Keddie, S., Eftimov, F., van den Berg, L.H., Brassington, R., de Haan, R.J. and van Schaik, I.N. (2022) Immunoglobulin for Multifocal Motor Neuropathy. Cochrane Database of Systematic Reviews, 2022, CD004429. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Sharawat, I.K., Panda, P., Dawman, L., Kasinathan, A. and Panda, P.K. (2025) Efficacy of Subcutaneous and Intravenous Immunoglobulin in Patients with Multifocal Motor Neuropathy: A Systematic Review and Meta-Analysis. Annals of Indian Academy of Neurology, 28, 485-494. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Al-Zuhairy, A., Sindrup, S.H. and Jakobsen, J. (2021) Long-Term Follow-Up of Facilitated Subcutaneous Immunoglobulin Therapy in Multifocal Motor Neuropathy. Journal of the Neurological Sciences, 427, Article ID: 117495. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Pestronk, A. (2003) Treatment of IgM Antibody Associated Polyneuropathies Using Rituximab. Journal of Neurology, Neurosurgery & Psychiatry, 74, 485-489. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Chaganti, S., Hannaford, A. and Vucic, S. (2022) Rituximab in Chronic Immune Mediated Neuropathies: A Systematic Review. Neuromuscular Disorders, 32, 621-627. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Budding, K., Johansen, L.E., Van de Walle, I., Dijkxhoorn, K., de Zeeuw, E., Bloemenkamp, L.M., et al. (2022) Anti-c2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy. Neurology Neuroimmunology & Neuroinflammation, 9, e1107. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Fitzpatrick, A.M., Mann, C.A., Barry, S., Brennan, K., Overell, J.R. and Willison, H.J. (2011) An Open Label Clinical Trial of Complement Inhibition in Multifocal Motor Neuropathy. Journal of the Peripheral Nervous System, 16, 84-91. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Lunn, M.P. and Nobile-Orazio, E. (2016) Immunotherapy for IgM Anti-Myelin-Associated Glycoprotein Paraprotein-Associated Peripheral Neuropathies. Cochrane Database of Systematic Reviews, 2016, CD002827. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Léger, J., Viala, K., Nicolas, G., Créange, A., Vallat, J., Pouget, J., et al. (2013) Placebo-Controlled Trial of Rituximab in IgM Anti-Myelin-Associated Glycoprotein Neuropathy. Neurology, 80, 2217-2225. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Tang, M.H., Mathis, S., Duffau, P., Cazenave, P., Solé, G., Duval, F., et al. (2020) Prognostic Factor of Poor Outcome in Anti-MAG Neuropathy: Clinical and Electrophysiological Analysis of a French Cohort. Journal of Neurology, 267, 561-571. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Parisi, M., Dogliotti, I., Clerico, M., Bertuzzo, D., Benevolo, G., Orsucci, L., et al. (2022) Efficacy of Rituximab in Anti‐Myelin‐Associated Glycoprotein Demyelinating Polyneuropathy: Clinical, Hematological and Neurophysiological Correlations during 2 Years of Follow‐Up. European Journal of Neurology, 29, 3611-3622. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Castellani, F., Visentin, A., Schirinzi, E., Salvalaggio, A., Cacciavillani, M., Candiotto, C., et al. (2023) Mutational Profile in 75 Patients with Anti-Myelin-Associated Glycoprotein Neuropathy. Neurology Neuroimmunology & Neuroinflammation, 10, e200122. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Castellani, F., Visentin, A., Campagnolo, M., Salvalaggio, A., Cacciavillani, M., Candiotto, C., et al. (2020) The Bruton Tyrosine Kinase Inhibitor Ibrutinib Improves Anti-Mag Antibody Polyneuropathy. Neurology Neuroimmunology & Neuroinflammation, 7, e720. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Querol, L. and Dalakas, M.C. (2025) The Discovery of Autoimmune Nodopathies and the Impact of IgG4 Antibodies in Autoimmune Neurology. Neurology Neuroimmunology & Neuroinflammation, 12, e200365. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Liu, B., Hu, J., Sun, C., Qiao, K., Xi, J., Zheng, Y., et al. (2023) Effectiveness and Safety of Rituximab in Autoimmune Nodopathy: A Single-Center Cohort Study. Journal of Neurology, 270, 4288-4295. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Tao, Z., Jiang, Y., Gui, Q. and Ma, J. (2026) Efficacy and Safety of Anti-CD20 Monoclonal Antibody Therapy for Autoimmune Nodopathies: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 17, Article ID: 1759210. [Google Scholar] [CrossRef]
|
|
[45]
|
Scheibe, F., Ostendorf, L., Prüss, H., Radbruch, H., Aschman, T., Hoffmann, S., et al. (2022) Daratumumab for Treatment‐Refractory Antibody‐Mediated Diseases in Neurology. European Journal of Neurology, 29, 1847-1854. [Google Scholar] [CrossRef] [PubMed]
|